Stifel Financial Corp Sells 18,218 Shares of Humana Inc. (NYSE:HUM)

Stifel Financial Corp trimmed its position in Humana Inc. (NYSE:HUM - Free Report) by 30.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,214 shares of the insurance provider's stock after selling 18,218 shares during the quarter. Stifel Financial Corp's holdings in Humana were worth $10,457,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of HUM. FPC Investment Advisory Inc. bought a new stake in shares of Humana in the 4th quarter worth approximately $27,000. Centricity Wealth Management LLC bought a new stake in Humana in the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA lifted its stake in Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Humana during the 4th quarter worth $33,000. Finally, Transce3nd LLC acquired a new position in shares of Humana in the 4th quarter worth $38,000. Institutional investors own 92.38% of the company's stock.

Analyst Ratings Changes

HUM has been the subject of several analyst reports. Mizuho upped their target price on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a report on Wednesday, April 9th. StockNews.com upgraded shares of Humana from a "hold" rating to a "buy" rating in a report on Monday, April 7th. Piper Sandler boosted their price target on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a report on Wednesday, January 15th. Truist Financial upped their price target on shares of Humana from $290.00 to $325.00 and gave the company a "hold" rating in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $284.90.

Humana Stock Down 1.6 %

Shares of Humana stock traded down $4.29 during midday trading on Tuesday, reaching $258.91. 2,471,973 shares of the company's stock traded hands, compared to its average volume of 1,750,020. The company has a market cap of $31.25 billion, a price-to-earnings ratio of 26.02, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company's 50 day simple moving average is $266.05 and its 200 day simple moving average is $270.76. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.37%. Humana's dividend payout ratio (DPR) is presently 35.58%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.